Ozempic’s expanded approval in the U.S. could transform how doctors treat patients with the condition, which involves a ...

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic top the list of 15 drugs selected for the second round of ...

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest ...

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

Chronic kidney disease affects about 37 million adults in the United States and is expected to rise. It is a common ...

The US plans to slash the price it pays for the Novo Nordisk A/S blockbusters Ozempic and Wegovy, the latest drugs to be ...

a list of 15 drugs under Medicare Part D, including Novo Nordisk's (NVO) blockbuster GLP-1s. Novo traded 4% lower on the news Friday. Diabetes drug Ozempic and weight-loss drug Wegovy top the list ...

The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...

Medicare price talks target 15 expensive drugs for 2027 PhRMA criticizes ... if they will participate in negotiations Novo Nordisk's shares fall after list release The price negotiation process ...

In other news, Novo Nordisk announced the results from its phase 3b STEP UP semaglutide trial today. Specifically, the ...

Few drugs have generated as much excitement as Novo Nordisk's (NYSE: NVO) Ozempic and Wegovy. The U.S. Food and Drug Administration (FDA) approved Ozempic in December 2017 for treating type 2 ...